Oncology Times

Coverage from 2019 ASCO Annual Meeting

Focus on Multiple Myeloma


 

Featured Content

New Article! Impact of Medicaid Expansion on Timely Cancer Treatment

Previous racial disparities in timely cancer treatment between African-American and white patients practically disappeared in states where Medicaid access was expanded under the Affordable Care Act (ACA), according to a new analysis of electronic health records of over 30,000 patients.

Read More

COLUMBA Study Updates

Dr. Maria-Victoria Mateos discusses findings from the Phase 3 COLUMBA study and impact on patient care.

New Video! Impact of CASSIOPEIA Study

Dr. Philippe Moreau reveals data from the Phase 3 CASSIOPEIA study and its impact on patient care.

Iberdomide in Combo With Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma

The first clinical results evaluating iberdomide (CC-220) in combination with dexamethasone in patients with relapsed and refractory multiple myeloma from the ongoing phase I/II CC-220-MM-001 study were released during an oral presentation at the 2019 ASCO Annual Meeting.

Read More

 

Loading